Choroidal Neovascularization Secondary to Diseases Other than Age-Related Macular Degeneration

Oishi, Akio

doi:10.1016/b978-0-12-805313-3.00008-9

Cited by 2 publications

(1 citation statement)

References 115 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Coat's disease [43], retinal vein occlusion [44] and choroidal haemangiomas [45]. Choroidal neovascular membranes can develop as a consequence of high myopia, ocular histoplasmosis, punctate inner choroiditis, multifocal choroiditis and central serous chorioretinopathy, as well as in macular telangiectasia [46]. While pathological angiogenesis shares some of the characteristics of physiological angiogenesis, it differs dramatically in that the resulting vessels are frequently dysfunctional being more tortuous, permeable and less-well perfused.…”

Section: Lrg1 Pathogenic Mechanisms Lrg1 As a Promoter Of Vascular Dysfunction And Pathological Angiogenesismentioning

confidence: 99%

LRG1 as a novel therapeutic target in eye disease

Rossi

Lobo

Greenwood

et al. 2022

Eye

View full text Add to dashboard Cite

Retinal and choroidal diseases are major causes of blindness and visual impairment in the developed world and on the rise due to an ageing population and diabetes epidemic. Standard of care is centred around blockade of vascular endothelial growth factor (VEGF), but despite having halved the number of patients losing sight, a high rate of patient non-response and loss of efficacy over time are key challenges. Dysregulation of vascular homoeostasis, coupled with fibrosis and inflammation, are major culprits driving sight-threatening eye diseases. Improving our knowledge of these pathological processes should inform the development of new drugs to address the current clinical challenges for patients. Leucine-rich α-2 glycoprotein 1 (LRG1) is an emerging key player in vascular dysfunction, inflammation and fibrosis. Under physiological conditions, LRG1 is constitutively expressed by the liver and granulocytes, but little is known about its normal biological function. In pathological scenarios, such as diabetic retinopathy (DR) and neovascular age-related macular degeneration (nvAMD), its expression is ectopically upregulated and it acquires a much better understood pathogenic role. Context-dependent modulation of the transforming growth-factor β (TGFβ) pathway is one of the main activities of LRG1, but additional roles have recently been emerging. This review aims to highlight the clinical and pre-clinical evidence for the pathogenic contribution of LRG1 to vascular retinopathies, as well as extrapolate from other diseases, functions which may be relevant to eye disease. Finally, we will provide a current update on the development of anti-LRG1 therapies for the treatment of nvAMD.

show abstract